The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | SEQUENCE: nab-paclitaxel/gemcitabine with modified FOLFOX in pancreatic cancer
Whilst nab-paclitaxel and gemcitabine are prescribed for patients with basal subtype of metastatic pancreatic cancer, FOLFIRINOX is the standard of care for patients with the classic subtype. Alfredo Carrato, MD, PhD, Hospital Ramón y Cajal, Madrid, Spain, discusses findings from the phase I SEQUENCE trial (NCT02504333) of nab-paclitaxel and gemcitabine followed by modified FOLFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients received the investigatory regimen over a six week period as first line treatment and a superior median overall survival (OS) rate was reported in receiving the novel combination. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
